News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
725,208 Results
Type
Article (41106)
Company Profile (265)
Press Release (683826)
Multimedia
Podcasts (84)
Webinars (20)
Section
Business (204783)
Career Advice (2026)
Deals (35551)
Drug Delivery (118)
Drug Development (81466)
Employer Resources (173)
FDA (16465)
Job Trends (14959)
News (346664)
Policy (32757)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2580)
Accelerated approval (38)
Adcomms (25)
Allergies (155)
Alliances (49605)
ALS (188)
Alzheimer's disease (1719)
Antibody-drug conjugate (ADC) (353)
Approvals (16756)
Artificial intelligence (570)
Autoimmune disease (209)
Automation (46)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (196)
Biotechnology (174)
Bladder cancer (174)
Brain cancer (61)
Breast cancer (677)
Cancer (5170)
Cardiovascular disease (431)
Career advice (1714)
Career pathing (38)
CAR-T (292)
CDC (51)
Celiac Disease (2)
Cell therapy (782)
Cervical cancer (40)
Clinical research (70046)
Collaboration (1822)
Company closure (4)
Compensation (1239)
Complete response letters (69)
COVID-19 (2722)
CRISPR (98)
C-suite (935)
Cystic fibrosis (145)
Data (6790)
Decentralized trials (2)
Denatured (25)
Depression (148)
Diabetes (537)
Diagnostics (6797)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (274)
Drug pricing (190)
Drug shortages (28)
Duchenne muscular dystrophy (264)
Earnings (90839)
Editorial (60)
Employer branding (21)
Employer resources (152)
Events (118126)
Executive appointments (1014)
FDA (19776)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (28)
Funding (1560)
Gene editing (209)
Generative AI (47)
Gene therapy (640)
GLP-1 (998)
Government (4685)
Grass and pollen (6)
Guidances (391)
Healthcare (18908)
HIV (70)
Huntington's disease (51)
IgA nephropathy (87)
Immunology and inflammation (266)
Immuno-oncology (76)
Indications (148)
Infectious disease (3025)
Inflammatory bowel disease (198)
Inflation Reduction Act (14)
Influenza (124)
Intellectual property (267)
Interviews (316)
IPO (16648)
IRA (50)
Job creations (3646)
Job search strategy (1429)
JPM (58)
Kidney cancer (18)
Labor market (91)
Layoffs (551)
Leadership (33)
Legal (7953)
Liver cancer (94)
Longevity (24)
Lung cancer (692)
Lymphoma (395)
Machine learning (51)
Management (59)
Manufacturing (879)
MASH (173)
Medical device (13829)
Medtech (13901)
Mergers & acquisitions (20032)
Metabolic disorders (1370)
mRNA (169)
Multiple sclerosis (172)
NASH (17)
Neurodegenerative disease (366)
Neuropsychiatric disorders (92)
Neuroscience (3065)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4523)
Now hiring (72)
Obesity (644)
Opinion (272)
Ovarian cancer (176)
Pain (220)
Pancreatic cancer (247)
Parkinson's disease (323)
Partnered (33)
Patents (536)
Patient recruitment (556)
Peanut (60)
People (59134)
Pharmaceutical (60)
Pharmacy benefit managers (30)
Phase 1 (21829)
Phase 2 (30829)
Phase 3 (22974)
Pipeline (6523)
Policy (303)
Postmarket research (2571)
Preclinical (9267)
Press Release (64)
Prostate cancer (267)
Psychedelics (49)
Radiopharmaceuticals (295)
Rare diseases (950)
Real estate (5958)
Recruiting (70)
Regulatory (24822)
Reports (54)
Research institute (2401)
Resumes & cover letters (353)
Rett syndrome (32)
RNA editing (16)
RSV (83)
Schizophrenia (154)
Series A (260)
Series B (195)
Service/supplier (11)
Sickle cell disease (102)
Special edition (22)
Spinal muscular atrophy (161)
Sponsored (43)
Startups (3623)
State (2)
Stomach cancer (18)
Supply chain (114)
Tariffs (84)
The Weekly (57)
Vaccines (1033)
Venture capital (93)
Weight loss (409)
Women's health (106)
Worklife (19)
Date
Today (84)
Last 7 days (576)
Last 30 days (3000)
Last 365 days (29939)
2026 (6744)
2025 (30177)
2024 (35222)
2023 (40079)
2022 (51179)
2021 (55712)
2020 (54090)
2019 (46542)
2018 (35023)
2017 (32111)
2016 (31484)
2015 (37562)
2014 (31322)
2013 (26357)
2012 (28577)
2011 (29273)
2010 (27334)
Location
Africa (737)
Alabama (87)
Alaska (7)
Arizona (324)
Arkansas (13)
Asia (39378)
Australia (6439)
California (12003)
Canada (3441)
China (1171)
Colorado (508)
Connecticut (514)
Delaware (357)
Europe (85129)
Florida (1810)
Georgia (381)
Hawaii (3)
Idaho (61)
Illinois (930)
India (74)
Indiana (551)
Iowa (22)
Japan (464)
Kansas (128)
Kentucky (43)
Louisiana (34)
Maine (73)
Maryland (1460)
Massachusetts (8588)
Michigan (339)
Minnesota (654)
Mississippi (6)
Missouri (135)
Montana (33)
Nebraska (29)
Nevada (132)
New Hampshire (81)
New Jersey (3187)
New Mexico (28)
New York (3155)
North Carolina (1528)
North Dakota (8)
Northern California (5919)
Ohio (356)
Oklahoma (21)
Oregon (41)
Pennsylvania (2420)
Puerto Rico (25)
Rhode Island (50)
South America (1111)
South Carolina (72)
South Dakota (1)
Southern California (4703)
Tennessee (195)
Texas (1866)
United States (42487)
Utah (361)
Vermont (1)
Virginia (282)
Washington D.C. (80)
Washington State (962)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
725,208 Results for "ucb inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
March 4, 2026
·
4 min read
Press Releases
Citizen Health Joins Forces with UCB to Accelerate Drug Development across Epilepsy and Rare Diseases
December 3, 2025
·
4 min read
Rare diseases
UCB Wins First FDA Approval for Ultra-Rare Mitochondrial Disease
Kygevvi is indicated for patients with thymidine kinase 2 deficiency whose symptoms arise by 12 years of age. The disease manifests as muscle weakness and can become life-threatening in severe instances.
November 4, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Lee’s Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights
December 10, 2025
·
6 min read
Press Releases
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
December 8, 2025
·
16 min read
Press Releases
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
December 8, 2025
·
6 min read
Press Releases
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
October 29, 2025
·
22 min read
Press Releases
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
August 29, 2025
·
40 min read
Alzheimer’s disease
Roche Trims Another Alzheimer’s Prospect, Ending UCB Collabortion
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
October 22, 2024
·
1 min read
·
Annalee Armstrong
Immunology and inflammation
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eye Second Phase III
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB are planning a second late-stage trial by the end of the year to support a drug application.
November 19, 2024
·
3 min read
·
Tristan Manalac
1 of 72,521
Next
